ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

Reversing Policy On Cancer Control Research, New Center Guidelines Top Accomplishments, Terry Believes

August 21, 1981

Advisory Council To Be Named For Alternative Medicine Cuts

May 27, 1994

Medicare: Clinton Budget Revives Proposal To End Physician Drug Markup

February 6, 1998

Guest Editorial: Group Chairs Urge Implementation of NCI plan. Next Step: Bioinformatics and Tissue Banks

November 11, 2011

Holland, Leader Win $250,00 Milken Awards: Six Others Get $50,000 Prizes

December 9, 1988

Broder Not Satisfied With Mortality STATS On Three Major Cancers

September 20, 1991